Eye on the Cure Podcast
The Eye on the Cure Podcast from the Foundation Fighting Blindness provides science information, news, and insights from the world of vision and retinal diseases. The podcasts are hosted by Ben Shaberman, vice president, science communications, and often include conversations with guests from the research and vision communities.
To learn more about our podcasts and which platforms they are available to stream, visit the Foundation Podcasts page. If you would like to download any of the episode transcripts, please visit the Eye on the Cure Podcast transcript page.
Episode 35: Kenji Fujita, MD
November 18, 2022. Kenji Fujita, MD, chief medical officer at Atsena Therapeutics, talks to host Ben Shaberman about retinal disease gene therapies including positive results from his company's gene therapy clinical trial for people with Leber congenital amaurosis 1 (GUCY2D mutations) as well as Atsena's emerging gene therapies for X-linked retinoschisis and Usher syndrome type 1B.
Episode 34: LambdaVision
November 4, 2022. In this episode of Eye on the Cure, host Ben Shaberman talks with LambdaVision's Nicole Wagner, PhD, and Jordan Greco, PhD, about the company's emerging protein-based artificial retina, the promise it holds for restoring vision, and the low-gravity, manufacturing experiments that have been conducted at the International Space Station.
Episode 33: Jacque Duncan, MD
October 7, 2022. Podcast host Ben Shaberman talks with Jacque Duncan, MD, a retinal specialist and clinical researcher at UCSF and chair of the Foundation's Scientific Advisory Board (SAB), about her work with adaptive optics for hi-resolution imaging of the retina, her challenging but rewarding role on the SAB, and how the research pipeline enables her to convey hope to all patients and families affected by inherited retinal diseases.
Episode 32: Dr. Sandy Greenberg
September 23, 2022. Dr. Sandy Greenberg talks to host Ben Shaberman about his incredible life's journey of going blind suddenly at the age of 19 to earning advanced degrees from Columbia and Harvard, receiving a White House Fellowship, serving on the Council of Foreign Relations, and founding the company which developed the computer system for the lunar excursion module that transported the first men to the moon. His compelling memoir, "Hello Darkness, My Old Friend," reflects on these and many other accomplishments as well as his lifelong friendship with Art Garfunkel. Dr. Greenberg and his wife, Sue, launched the Campaign to End Blindness to generously fund vision-restoring research.
Episode 31: Jean Bousquet
September 9, 2022. Jean Bousquet, a certified orientation and mobility specialist with the Office of Rehabilitation Services in Rhode Island, talks to podcast host Ben Shaberman about navigational canes, guide dogs, phone apps, and many other orientation and mobility resources for people with low vision.
Episode 30: Steven McCoy
August 19, 2022. Host Ben Shaberman talks with Steven McCoy, who overcame early challenges as a kid with Usher syndrome, to become the first black, deaf-blind journalist. Steven found his way forward through an impressive career with Disney and his own projects including his "Sessions with Steven" podcast and forthcoming memoir and television film about his remarkable personal journey.
Episode 29: David Gamm, MD, PhD
August 5, 2022. Stem cell expert David Gamm, MD, PhD, talks with host Ben Shaberman about his innovative work in stem cell therapy development for retinal diseases, including his research at the University of Wisconsin-Madison and the company Opsis, which he co-founded. Their conversation covers a variety of topics including induced pluripotent stem cells, the benefits of scaffolds for cell orientation in the retina, and scale-up manufacturing.
Episode 28: Brian Strem, PhD
July 22, 2022. Brian Strem, PhD, CEO of Kiora Pharmaceuticals, talks to Ben Shaberman about his company's emerging gene-agnostic small molecule for restoring vision for people with advanced retinitis pigmentosa and potentially other retinal diseases. Kiora recently received authorization in Australia to launch a trial for the treatment.
Episode 27: Jeff Stern and Sally Temple
July 8, 2022. Jeff Stern, MD, PhD, and Sally Temple, PhD, co-founders of the Neural Stem Cell Institute, talk with host Ben Shaberman about their discovery of stem cells in the human retinal pigment epithelium and their newly launched clinical trial for the cells in people with dry age-related macular degeneration.
Episode 26: Rachel Wong, PhD
June 25, 2022. Rachel Wong, PhD, professor and chair of the Department of Biological Structure at the University of Washington in Seattle, discusses the beauty and complexity of retinal circuitry and why the work in her lab is so important to the advancement of treatments and cures for people with inherited retinal diseases. Dr. Wong delivered the prestigious Friedenwald Award Lecture at the 2022 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Episode 25: Frank Bruni
June 10, 2022. Frank Bruni, a popular NY Times columnist, book author, and Duke journalism professor, talks with host Ben Shaberman about his eclectic career, journey with vision loss, and latest book, "The Beauty of Dusk."
Episode 24: Ash Jayagopal, PhD
May 6, 2022. Host Ben Shaberman talks with Ash Jayagopal, chief scientific officer at Opus Genetics, a company launched by the Foundation Fighting Blindness to advance gene therapies for inherited retinal diseases into clinical trials. The company is targeting rare retinal conditions, including forms of Leber congenital amaurosis, that aren't being addressed by other companies.
Episode 23: John Flannery, PhD
April 22, 2022. John Flannery, PhD, a renowned gene therapy researcher from UC Berkeley and co-founder of Vedere Bio, talks with host, Ben Shaberman, about the promise of optogenetics, a gene-agnostic approach for restoring vision for people with advanced retinal diseases.
Episode 22: Judge David Tatel
April 8, 2022. Host Ben Shaberman chats with Judge David Tatel, who, since 1994, has served on the US Court of Appeals — DC Circuit. He was appointed to the court by President Bill Clinton when Ruth Bader Ginsburg was appointed to the Supreme Court. During the podcast interview, David reflects on his impressive career, his adjustments to vision loss from XLRP, and his beloved guide dog, Vixen.
Episode 21: Katriona Taylor
March 25, 2022. Jazz singer Katriona Taylor talks with host Ben Shaberman about her journey with Stargardt disease and her new album, Blind Passion, which includes covers of songs from iconic singers such as Stevie Wonder, Ray Charles, and Diane Schuur. Katriona also shares a performance of her original song "In the Name of Love."
Episode 20: Dr. Nancy Holekamp
March 11, 2022. Dr. Nancy Holekamp, a retinal specialist, clinical trial investigator, and key opinion leader in the retinal disease space, discusses new therapies and research for wet and dry age-related macular degeneration and some emerging treatment approaches for inherited retinal diseases. This episode is sponsored by Apellis Pharmaceuticals.
Episode 19: Nieraj Jain, MD
February 25, 2022. Ben Shaberman talks with Nieraj Jain, MD, a retinal surgeon and expert in inherited retinal diseases from Emory on a wide range of clinical topics including retinal surgeries, vitamin A for IRD patients, cataract surgery for IRD patients, and his role in the Phase 3 XLRP gene therapy clinical trial being conducted by MeiraGTx/Janssen.
Episode 18: Michael Stone
February 11, 2022. Ben Shaberman talks with Michael Stone, a 17-time Ironman triathlete, about the adventures and challenges of being a prolific athlete with vision loss and a really fast guide dog.
Episode 17: Tom Reh, PhD
January 28, 2022. Eye on the Cure host, Ben Shaberman, talks with world-renowned researcher Tom Reh, PhD, who is developing an approach to enable the degenerating retina to regenerate its own new photoreceptors.
Episode 16: Ben Mehl
January 14, 2022. Podcast host, Ben Shaberman, has a fun chat with Ben Mehl, an actor with Stargardt disease who plays a completely blind librarian on the hit Netflix series "You."
Episode 15: Gordon Gund
December 10, 2021. Gordon Gund, co-founder and chairman emeritus of the Foundation, joins host Ben Shaberman to share reflections on 50 years of fighting blindness and what has made the Foundation successful in driving its mission to eradicate the entire spectrum of retinal degenerative diseases.
Episode 14: Michael Kalberer
November 19, 2021. Michael Kalberer talks with Ben Shaberman about his perspective on living with cerebral palsy and Leber congenital amaurosis as well as his vision improvements after receiving an emerging CRISPR/Cas9 treatment in Editas' BRILLIANCE clinical trial.
Episode 13: Dave Knop, PhD
November 5, 2021. Ben Shaberman talks with Dave Knop, PhD, vice president of process development at AGTC, about how emerging gene therapies for inherited retinal diseases are manufactured for use in human studies.
Episode 12: Michael Young, PhD
October 22, 2021. Michael Young, PhD, from Harvard Medical School, joins host Ben Shaberman to talk about the latest in stem cell research for retinal diseases.
Episode 11: Silvia Sorensen, PhD
October 8, 2021. Silvia Sorensen, PhD, an associate professor at the University of Rochester in the Center for Community Health and Prevention, talks with host Ben Shaberman about mental health issues and management for people with low vision.
Episode 10: Dr. Naveed Shams, ProQR
September 24, 2021. Dr. Naveed Shams, chief scientific officer at ProQR, discusses RNA therapies and ProQR's three clinical trials targeting: Leber congenital amaurosis (a CEP290 mutation), USH2A exon 13, and retinitis pigmentosa (RHO-P23H).
Episode 9: Stephen Daiger, PhD
September 10, 2021. Stephen Daiger, PhD, Director of the Laboratory for Molecular Diagnosis of Inherited Eye Diseases at UT Houston, discusses the challenges and advancements in identifying the genetic mutations that cause retinal degenerative diseases.
Episode 8: Ben Shaberman, Genetic Testing
August 27, 2021. Host Ben Shaberman provides an overview of the Foundation's no-cost genetic testing program for people in the U.S. with inherited retinal diseases.
Episode 7: Bonnie Swenor, MPH, PhD
August 13, 2021. Host Ben Shaberman talks with Bonnie Swenor, MPH, PhD, Director of the Johns Hopkins Disability Health Research Center, about her journey from the sudden, unexpected onset of vision loss to becoming a researcher and advocate for people with all disabilities.
Episode 6: Drs. Troyk and Lane
July 30, 2021. Ben Shaberman interviews Drs. Philip Troyk and Frank Lane of the Illinois Institute of Technology about their clinical trial for the Intracortical Vision Prosthesis, a pioneering system for restoring vision to people who are completely blind.
Episode 5: Morten Bonde
July 16, 2021. Ben Shaberman chats with Morten Bonde, senior art director at Lego Group in Copenhagen and author of the book "Sentenced to Blindness — Now What?"
Episode 4: Jill Dolgin, AGTC
July 2, 2021. Jill Dolgin, the executive director of patient advocacy at AGTC, talks to Ben about her role in helping patients understand clinical research. They also discuss AGTC's current gene therapy clinical trials for X-linked retinitis pigmentosa and achromatopsia.
Episode 3: Dr. Daniel Chung
June 18, 2021. Host Ben Shaberman interviews Dr. Daniel Chung, chief medical officer at SparingVision, which is developing a gene-agnostic therapy to preserve cone vision in people with retinitis pigmentosa, Usher syndrome, and related conditions. A clinical trial launch for the emerging treatment, known as SPVN06, is planned for late 2021 or early 2022.
Episode 2: Sheila Nirenberg, PhD
May 28, 2021. Sheila Nirenberg, PhD, a professor at Cornell and founder at Bionic Sight talks with Ben Shaberman about her company's innovative optogenetic therapy which provides hope for vision restoration for people with advanced vision loss from retinal diseases. The approach has shown encouraging results in an early stage clinical trial.
Episode 1: Welcome
May 14, 2021. In the inaugural Eye on the Cure podcast, host Ben Shaberman explains why the retina is such a great target for therapy development and also provides some updates from the clinical trial frontlines.